Maria Frantzi

List of Publications by Year
in descending order

38 papers	1,119 citations	394421 19 h-index	414414 32 g-index
42 all docs	42 docs citations	42 times ranked	1900 citing authors

#	Article	IF	Citations
1	A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data. Cancers, 2022, 14, 1995.	3.7	5
2	Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene Signature. Cancers, 2022, 14, 2542.	3.7	3
3	Validation of diagnostic nomograms based on CEâ€"MS urinary biomarkers to detect clinically significant prostate cancer. World Journal of Urology, 2022, 40, 2195-2203.	2.2	4
4	Pathophysiological Implications of Urinary Peptides in Hepatocellular Carcinoma. Cancers, 2021, 13, 3786.	3.7	7
5	Proteomeâ€"based classification of Nonmuscle Invasive Bladder Cancer. International Journal of Cancer, 2020, 146, 281-294.	5.1	35
6	Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma. Journal of Biomedical Science, 2020, 27, 13.	7.0	19
7	Drug repurposing in oncology. Lancet Oncology, The, 2020, 21, e543.	10.7	20
8	A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patientsâ€™ Omics Signatures. Cancers, 2020, 12, 3519.	3.7	12
9	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 383-400.	0.7	4
10	Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer. Diagnostics, 2020, 10, 658.	2.6	7
11	Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation. Diagnostics, 2020, 10, 655.	2.6	12
12	Proteomics biomarkers for solid tumors: Current status and future prospects. Mass Spectrometry Reviews, 2019, 38, 49-78.	5.4	53
13	Urinary peptide panel for prognostic assessment of bladder cancer relapse. Scientific Reports, 2019, 9, 7635.	3.3	12
14	CEâ€"MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. British Journal of Cancer, 2019, 120, 1120-1128.	6.4	25
15	Peptidomics and proteomics based on CEâ€"MS as a robust tool in clinical application: The past, the present, and the future. Electrophoresis, 2019, 40, 2294-2308.	2.4	89
16	Proteomics in Drug Development: The Dawn of a New Era?. Proteomics - Clinical Applications, 2019, 13, e1800087.	1.6	48
17	Clinical Proteomics on the Path Toward Implementation: First Promises Delivered. Proteomics - Clinical Applications, 2019, 13, e1800094.	1.6	3
18	Urinary proteomic biomarkers in oncology: ready for implementation?. Expert Review of Proteomics, 2019, 16, 49-63.	3.0	4

#	Article	IF	Citations
19	Urinary Glycopeptide Analysis for the Investigation of Novel Biomarkers. Proteomics - Clinical Applications, 2019, 13, e1800111.	1.6	17
20	Proteomics and Metabolomics for AKI Diagnosis. Seminars in Nephrology, 2018, 38, 63-87.	1.6	59
21	Urinary CE-MS peptide marker pattern for detection of solid tumors. Scientific Reports, 2018, 8, 5227.	3.3	28
22	Clinical Proteomics for Precision Medicine: The Bladder Cancer Case. Proteomics - Clinical Applications, 2018, 12, 1700074.	1.6	21
23	Promise and Implementation of Proteomic Prostate Cancer Biomarkers. Diagnostics, 2018, 8, 57.	2.6	9
24	Clinical Proteomics: Closing the Gap from Discovery to Implementation. Proteomics, 2018, 18, e1700463.	2.2	24
25	Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions. Bladder Cancer, 2017, 3, 1-18.	0.4	24
26	Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention. Oncotarget, 2017, 8, 69435-69455.	1.8	27
27	Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. Clinical Cancer Research, 2016, 22, 4077-4086.	7.0	90
28	Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of â€"omics findings. Scientific Reports, 2016, 6, 25619.	3.3	12
29	Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models. Oncotarget, 2016, 7, 70750-70768.	1.8	19
30	Developing proteomic biomarkers for bladder cancer: towards clinical application. Nature Reviews Urology, 2015, 12, 317-330.	3.8	69
31	Recent progress in urinary proteome analysis for prostate cancer diagnosis and management. Expert Review of Molecular Diagnostics, 2015, 15, 1539-1554.	3.1	13
32	Targeting the Proteome of Cellular Fractions: Focus on Secreted Proteins. Methods in Molecular Biology, 2015, 1243, 29-41.	0.9	1
33	Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development. Clinical and Translational Medicine, 2014, 3, 7.	4.0	105
34	Discovery and validation of urinary biomarkers for detection of renal cell carcinoma. Journal of Proteomics, 2014, 98, 44-58.	2.4	64
35	IMAC Fractionation in Combination with LCâ€"MS Reveals H2B and NIF-1 Peptides As Potential Bladder Cancer Biomarkers. Journal of Proteome Research, 2013, 12, 3969-3979.	3.7	20
36	Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on bladder cancer. Proteomics - Clinical Applications, 2013, 7, 779-793.	1.6	26

#	Article	IF	Citations
37	Biomarkers for bladder cancer aggressiveness. Current Opinion in Urology, 2012, 22, 390-396.	1.8	32
38	Profilin 1 is a Potential Biomarker for Bladder Cancer Aggressiveness. Molecular and Cellular Proteomics, 2012, 11, M111.009449.	3.8	97